| Protocol Number |
Study Title |
|
CALGB 100104 |
A Phase III Randomized, Double-Blind Study of Maintenance Therapy with
CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
|
|
CALGB 10403 |
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia
|
|
CALGB 10404 |
A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia |
|
CALGB 10502 |
Dose Escalation and Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years |
|
CALGB 10503 |
Phase II Study of Maintenance Therapy with Decitabine Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 Years
|
|
CALGB 10603 |
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients
< 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
|
|
CALGB 140503 |
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
|
|
CALGB 170601 |
A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain
Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN)
|
|
CALGB 20202 |
AML Companion-Novel markers |
|
CALGB 30504 |
Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study |
|
CALGB 30506 |
A Randomized Phase III Trial of Adjuvant Therapy in Early Stage Non-Small Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy |
|
CALGB 30605 |
A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer
|
|
CALGB 30607 |
Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced,
Stage IIIB/IV Non-Small Cell Lung Cancer
|
|
CALGB 30610 |
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide |
|
CALGB 30704 |
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
|
CALGB 30801 |
A Randomized Phase III Double Blind Trial Evaluating Selective Cox-2 Inhibition In Cox-2 Expressing Advanced Non-Small Cell Lung Cancer |
|
CALGB 30901 |
Randomized Phase II Study of Maintenance Pemetrexed versus Observation for Patients with Malignant Pleural Mesothelioma without Progression after
First-Line Chemotherapy
|
|
CALGB 360401 |
Temp clos 1/21/09
Age 65-69 cohort closed 6/9/08
Development of a Geriatric Assessment Measure for Older Patients with Cancer |
|
CALGB 40101 |
Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study |
|
CALGB 40302 |
Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer |
|
CALGB 40502 |
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone
Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
|
|
CALGB 40503 |
Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer |
|
CALGB 40601 |
Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer |
|
CALGB 40603 |
Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin and/or Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer |
|
CALGB 50303 |
Phase III Randomized Study of R-CHOP vs Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas |